Erratum to: Immune-Related Antigens, Surface Molecules and Regulatory Factors in Human-Derived Mesenchymal Stromal Cells: The Expression and Impact of Inflammatory Priming(Stem Cell Rev and Rep, 10.1007/s12015-012-9408-1);Immune-Related Antigens, Surface Molecules and Regulatory Factors in Human-Derived Mesenchymal Stromal Cells: The Expression and Impact of Inflammatory Priming

Stem Cell Reviews and Reports

Volumn 8, Issue 4, 2012, Pages 1188-1198

  Najar, Mehdi ^a   Raicevic, Gordana ^a   Kazan, Hussein Fayyad ^a   de Bruyn, Cécile ^a   Bron, Dominique ^a   Toungouz, Michel ^a   Lagneaux, Laurence ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Cell adhesion molecules; Immune related antigens; Immunological profile; Immunoregulatory factors; Inflammation; Mesenchymal stromal cells; Tissue sources

Indexed keywords

EID: 84870342780     PISSN: 15508943     EISSN: 15586804     Source Type: Journal    
DOI: 10.1007/s12015-012-9415-2     Document Type: Erratum

References (64)

1. Friedenstein, A. J., Petrakova, K. V., Kurolesova, A. I., & Frolova, G. P. (1968). Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation, 6, 230-247.
2. Tondreau, T., Meuleman, N., Delforge, A., et al. (2005). Mesenchymal stem cells derived from CD133-positive cells in mobilized peripheral blood and cord blood: proliferation, Oct4 expression, and plasticity. Stem Cells, 23, 1105-1112.
3. Zuk, P. A., Zhu, M., Mizuno, H., et al. (2001). Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Engineering, 7, 211-228.
4. Campagnoli, C., Roberts, I. A., Kumar, S., Bennett, P. R., Bellantuono, I., & Fisk, N. M. (2001). Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood, 98, 2396-2402.
5. Pittenger, M. F., Mackay, A. M., Beck, S. C., et al. (1999). Multilineage potential of adult human mesenchymal stem cells. Science, 284, 143-147.
6. Keating, A. (2006). Mesenchymal stromal cells. Current Opinion in Hematology, 13, 419-425.
7. Arthur, A., Zannettino, A., & Gronthos, S. (2009). The therapeutic applications of multipotential mesenchymal/stromal stem cells in skeletal tissue repair. Journal of Cellular Physiology, 218, 237-245.
8. Mosna, F., Sensebé, L., & Krampera, M. (2010). Human bone marrow and adipose tissue mesenchymal stem cells: a user's guide. Stem Cells and Development, 19, 1449-1470.
9. Fan, C. G., Zhang, Q. J., & Zhou, J. R. (2011). Therapeutic potentials of mesenchymal stem cells derived from human umbilical cord. Stem Cell Reviews and Reports, 7, 195-207.
10. Marigo, I., & Dazzi, F. (2011). The immunomodulatory properties of mesenchymal stem cells. Seminars in Immunopathology, 33, 593-602.
11. Najar, M., Raicevic, G., Boufker, H. I., et al. (2010). Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. Cellular Immunology, 264, 171-179.
12. Najar, M., Raicevic, G., Boufker, H. I., et al. (2010). Adipose-tissue-derived and Wharton's jelly-derived mesenchymal stromal cells suppress lymphocyte responses by secreting leukemia inhibitory factor. Tissue Engineering. Part A, 16, 3537-3546.
13. Dazzi, F., & Krampera, M. (2011). Mesenchymal stem cells and autoimmune diseases. Best Practice & Research. Clinical Haematology, 24, 49-57.
14. Kebriaei, P., & Robinson, S. (2011). Treatment of graft-versus-host-disease with mesenchymal stromal cells. Cytotherapy, 13, 262-268.
15. Tolar, J., Le Blanc, K., Keating, A., & Blazar, B. R. (2010). Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells, 28, 1446-1455.
16. De Bruyn, C., Najar, M., Raicevic, G., et al. (2011). A rapid, simple, and reproducible method for the isolation of mesenchymal stromal cells from Wharton's Jelly without enzymatic treatment. Stem Cells and Development, 20, 547-557.
17. Najar, M., Raicevic, G., Boufker, H. I., et al. (2010). Modulated expression of adhesion molecules and galectin-1: role during mesenchymal stromal cell immunoregulatory functions. Experimental Hematology, 38, 922-932.
18. Dominici, M., Le Blanc, K., Mueller, I., et al. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8, 315-317.
19. Campioni, D., Rizzo, R., Stignani, M., et al. (2009). A decreased positivity for CD90 on human mesenchymal stromal cells (MSCs) is associated with a loss of immunosuppressive activity by MSCs. Cytometry. Part B, Clinical Cytometry, 76, 225-230.
20. Wiesmann, A., Bühring, H. J., Mentrup, C., & Wiesmann, H. P. (2006). Decreased CD90 expression in human mesenchymal stem cells by applying mechanical stimulation. Head & Face Medicine, 2, 8.
21. Jin, H. J., Park, S. K., Oh, W., Yang, Y. S., Kim, S. W., & Choi, S. J. (2009). Down-regulation of CD105 is associated with multi-lineage differentiation in human umbilical cord blood-derived mesenchymal stem cells. Biochemical and Biophysical Research Communications, 381, 676-681.
22. Sun, Z., Han, Q., Zhu, Y., et al. (2011). NANOG has a role in mesenchymal stem cells' immunomodulatory effect. Stem Cells and Development, 20, 1521-1528.
23. Mafi, P., Hindocha, S., Mafi, R., Griffin, M., & Khan, W. S. (2011). Adult mesenchymal stem cells and cell surface characterization - a systematic review of the literature. Open Orthopaedics Journal, 5, 253-260.
24. Szöke, K., Beckstrøm, K. J., & Brinchmann, J. E. (2012). Human adipose tissue as a source of cells with angiogenic potential. Cell Transplantation, 21, 235-250.
25. Suga, H., Matsumoto, D., Eto, H., et al. (2009). Functional implications of CD34 expression in human adipose-derived stem/progenitor cells. Stem Cells and Development, 18, 1201-1210.
26. Jersmann, H. P. (2005). Time to abandon dogma: CD14 is expressed by non-myeloid lineage cells. Immunology & Cell Biology, 83, 462-467.
27. Yu, G., Wu, X., Dietrich, M. A., et al. (2010). Yield and characterization of subcutaneous human adipose-derived stem cells by flow cytometric and adipogenic mRNA analyzes. Cytotherapy, 12, 538-546.
28. Yeh, S. P., Chang, J. G., Lo, W. J., et al. (2006). Induction of CD45 expression on bone marrow-derived mesenchymal stem cells. Leukemia, 20, 894-896.
29. Frauwirth, K. A., & Thompson, C. B. (2002). Activation and inhibition of lymphocytes by costimulation. Journal of Clinical Investigation, 109, 295-299.
30. Le Blanc, K., Tammik, C., Rosendahl, K., Zetterberg, E., & Ringdén, O. (2003). HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Experimental Hematology, 31, 890-896.
31. Romieu-Mourez, R., François, M., Boivin, M. N., Stagg, J., & Galipeau, J. (2007). Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density. The Journal of Immunology, 179, 1549-1558.
32. Briones, J., Novelli, S., & Sierra, J. (2011). T-cell costimulatory molecules in acute-graft-versus host disease: therapeutic implications. Bone Marrow Research, 2011, 976793.
33. de la Garza-Rodea, A. S., Verweij, M. C., Boersma, H., et al. (2011). Exploitation of herpesvirus immune evasion strategies to modify the immunogenicity of human mesenchymal stem cell transplants. PLoS One, 6, e14493.
34. Pachón-Peña, G., Yu, G., Tucker, A., et al. (2011). Stromal stem cells from adipose tissue and bone marrow of age-matched female donors display distinct immunophenotypic profiles. Journal of Cellular Physiology, 226, 843-851.
35. Brooke, G., Tong, H., Levesque, J. P., & Atkinson, K. (2008). Molecular trafficking mechanisms of multipotent mesenchymal stem cells derived from human bone marrow and placenta. Stem Cells and Development, 17, 929-940.
36. De Ugarte, D. A., Alfonso, Z., Zuk, P. A., et al. (2003). Differential expression of stem cell mobilization-associated molecules on multi-lineage cells from adipose tissue and bone marrow. Immunology Letters, 89, 267-270.
37. Zhu, H., Mitsuhashi, N., Klein, A., et al. (2006). The role of the hyaluronan receptor CD44 in mesenchymal stem cell migration in the extracellular matrix. Stem Cells, 24, 928-935.
38. Zöller, M. (2011). CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nature Reviews. Cancer, 11, 254-267.
39. Leir, S. H., Holgate, S. T., & Lackie, P. M. (2003). Inflammatory cytokines can enhance CD44-mediated airway epithelial cell adhesion independently of CD44 expression. American Journal of Physiology. Lung Cellular and Molecular Physiology, 285, L1305-L1311.
40. Crop, M. J., Baan, C. C., Korevaar, S. S., et al. (2010). Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells. Clinical and Experimental Immunology, 162, 474-486.
41. Götherström, C., West, A., Liden, J., Uzunel, M., Lahesmaa, R., & Le Blanc, K. (2005). Difference in gene expression between human fetal liver and adult bone marrow mesenchymal stem cells. Haematologica, 90, 1017-1026.
42. Boquest, A. C., Shahdadfar, A., Frønsdal, K., et al. (2005). Isolation and transcription profiling of purified uncultured human stromal stem cells: alteration of gene expression after in vitro cell culture. Molecular Biology of the Cell, 16, 1131-1141.
43. Kranz, A., Wagner, D. C., Kamprad, M., et al. (2010). Transplantation of placenta-derived mesenchymal stromal cells upon experimental stroke in rats. Brain Research, 1315, 128-136.
44. Alipour, R., Sadeghi, F., Hashemi-Beni, B., et al. (2010). Phenotypic characterizations and comparison of adult dental stem cells with adipose-derived stem cells. International Journal of Preventive Medicine, 1, 164-171.
45. Halfon, S., Abramov, N., Grinblat, B., & Ginis, I. (2011). Markers distinguishing mesenchymal stem cells from fibroblasts are downregulated with passaging. Stem Cells and Development, 20, 53-66.
46. Schugar, R. C., Chirieleison, S. M., Wescoe, K. E., et al. (2009). High harvest yield, high expansion, and phenotype stability of CD146 mesenchymal stromal cells from whole primitive human umbilical cord tissue. Journal of Biomedicine and Biotechnology, 2009, 789526.
47. Haskó, G., Deitch, E. A., Szabó, C., Németh, Z. H., & Vizi, E. S. (2002). Adenosine: a potential mediator of immunosuppression in multiple organ failure. Current Opinion in Pharmacology, 2, 440-444.
48. Sundin, M., D'arcy, P., Johansson, C. C., et al. (2011). Multipotent mesenchymal stromal cells express FoxP3: a marker for the immunosuppressive capacity? Journal of Immunotherapy, 34, 336-342.
49. Niemelä, J., Henttinen, T., Yegutkin, G. G., et al. (2004). IFN-alpha induced adenosine production on the endothelium: a mechanism mediated by CD73 (ecto-5'-nucleotidase) up-regulation. The Journal of Immunology, 172, 1646-1653.
50. Saldanha-Araujo, F., & Panepucci, R. A. (2011). CD39 expression in mesenchymal stromal cells. Journal of Immunotherapy, 34, 568.
51. Lepperdinger, G. (2011). Inflammation and mesenchymal stem cell aging. Current Opinion in Immunology, 23, 518-524.
52. Rizzo, R., Lanzoni, G., Stignani, M., et al. (2011). A simple method for identifying bone marrow mesenchymal stromal cells with a high immunosuppressive potential. Cytotherapy, 13, 523-527.
53. Avanzini, M. A., Bernardo, M. E., Cometa, A. M., et al. (2009). Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood- and bone marrow-derived progenitors. Haematologica, 94, 1649-1660.
54. Wiendl, H., Mitsdoerffer, M., Schneider, D., et al. (2003). Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. The FASEB Journal, 17, 1892-1894.
55. Anzalone, R., Lo Iacono, M., Loria, T., et al. (2011). Wharton's jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes. Stem Cell Reviews and Reports, 7, 342-363.
56. Kronsteiner, B., Wolbank, S., Peterbauer, A., et al. (2011). Human mesenchymal stem cells from adipose tissue and amnion influence T-cells depending on stimulation method and presence of other immune cells. Stem Cells and Development, 20, 2115-2126.
57. Fazekasova, H., Lechler, R., Langford, K., & Lombardi, G. (2011). Placenta-derived MSCs are partially immunogenic and less immunomodulatory than bone marrow-derived MSCs. Journal of Tissue Engineering and Regenerative Medicine, 5, 684-694.
58. Zarnegar, R. (1995). Regulation of HGF and HGFR gene expression. EXS, 74, 33-49.
59. Grellier, P., Yee, D., Gonzalez, M., & Abboud, S. L. (1995). Characterization of insulin-like growth factor binding proteins (IGFBP) and regulation of IGFBP-4 in bone marrow stromal cells. British Journal of Haematology, 90, 249-257.
60. van Buul-Offers, S. C., & Kooijman, R. (1998). The role of growth hormone and insulin-like growth factors in the immune system. Cellular and Molecular Life Sciences, 54, 1083-1094.
61. Gieseke, F., Schütt, B., Viebahn, S., et al. (2007). Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFNgammaR1 signaling and IDO expression. Blood, 110, 2197-2200.
62. Liu, C. H., & Hwang, S. M. (2005). Cytokine interactions in mesenchymal stem cells from cord blood. Cytokine, 32, 270-279.
63. Wilson, H. M., Lesnikov, V., Plymate, S. R., Ward, J., & Deeg, H. J. (2005). High IGFBP-3 levels in marrow plasma in early-stage MDS: effects on apoptosis and hemopoiesis. Leukemia, 19, 580-585.
64. Chen, J., Li, J., Lim, F. C., et al. (2010). Maintenance of naïve CD8 T cells in nonagenarians by leptin, IGFBP3 and T3. Mechanisms of Ageing and Development, 131, 29-37.